Evidence / Rainey-Smith et al. · 2016
A year-long curcumin cognition trial
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind, placebo-controlled human trial.
- Product relevance
- Ingredient research involving turmeric extracts or curcuminoids.
- Sample or population
- 96 community-dwelling older adults in the reported analysis.
- Studied dose
- 1,500 mg/day of the studied curcumin formulation or placebo.
- Duration
- 12 months.
- Finding
- A difference over time on the Montreal Cognitive Assessment was driven by a decline in the placebo group at six months. The other reported clinical and cognitive measures showed no between-group differences.
- Limitations
- The finding on one screening measure does not establish a broad cognitive benefit or prevention of decline. The tested formulation differs from the DR.MORGAN product.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- The McCusker Alzheimer's Research Foundation and Hollywood Private Hospital Research Foundation supported the work. The authors declared no conflicts.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
High-Potency Turmeric Extract · NPN 80143038
Source of (an) antioxidant(s)/Provides (an) antioxidant(s) that help(s) fight/protect (cell) against/reduce (the oxidative effect of/the oxidative damage caused by/cell damage caused by) free radicals.